Clinical Trial

Impact of a Biophoton Therapy on Patients With Brain Disorders

Study acronym: Alzheimer
Recruiting
View on ClinicalTrials.gov →
Summary
Previous clinical studies revealed that the newly developed biophoton therapy has been safe and effective in treating patients with Alzheimer's disease, dementia, stroke, traumatic brain injury, or Parkinson's disease. The current study is to confirm the previous clinical observation by conducting as a randomized, triple-blinded, placebo-controlled prospective intervention clinical research. About 80 patients with brain disorder (Alzheimer's disease, dementia, stroke, traumatic brain injury, Parkinson's disease) will participate in the intervention clinical study at the Tesla MedBed Center located in Butler, PA.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-11-17; most recent amendment 2025-08-04.
Trial Details
NCT Number NCT06147999
Lead Sponsor First Institute of All Medicines
Conditions Brain Disorders - Alzheimer's Disease, Dementia, Parkinson's Disease, Traumatic Brain Injury
Enrollment 80 participants
Start Date 2023-11-08
Primary Completion 2026-11-08 (estimated)
Study Completion 2026-11-08 (estimated)
Updated on ClinicalTrials.gov 2025-08-08